Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Operating Expenses: 2021-2025

Historic Other Operating Expenses for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Sep 2025 value amounting to $25.5 million.

  • Mirum Pharmaceuticals' Other Operating Expenses rose 22.74% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.8 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $81.6 million for FY2024, which is 73.56% up from last year.
  • Mirum Pharmaceuticals' Other Operating Expenses amounted to $25.5 million in Q3 2025, which was up 9.03% from $23.4 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Other Operating Expenses ranged from a high of $25.5 million in Q3 2025 and a low of $1.9 million during Q4 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $20.8 million (2024), whereas its average is $18.2 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Other Operating Expenses surged by 456.74% in 2023, and later declined by 8.95% in 2024.
  • Quarterly analysis of 5 years shows Mirum Pharmaceuticals' Other Operating Expenses stood at $1.9 million in 2021, then surged by 136.15% to $4.5 million in 2022, then skyrocketed by 456.74% to $25.0 million in 2023, then decreased by 8.95% to $22.8 million in 2024, then rose by 22.74% to $25.5 million in 2025.
  • Its last three reported values are $25.5 million in Q3 2025, $23.4 million for Q2 2025, and $23.0 million during Q1 2025.